Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

Katherine Luzuriaga, Yvonne Bryson, George McSherry, James Robinson, Barbara Stechenberg, Gwendolyn Scott, Michael Lamson, Susannah Cort, John L. Sullivan

Research output: Contribution to journalArticlepeer-review

72 Scopus citations


Phase 1 trials were conducted in human immunodeficiency virus type 1 (HIV-1)-infected children to examine the pharmacokinetics, safety, and antiretroviral activity of nevirapine, a nonnucleoside HIV-1 reverse transcriptase inhibitor. Nevirapine was rapidly absorbed, but the time to peak plasma concentrations increased with higher doses. Clearance was more rapid in chronic dosing studies than predicted by single-dose studies and was more rapid in younger children than in adolescent children. Rash, which occurred in 1 of the 21 study participants, was the single toxicity regarded as nevirapine-related. At doses ≤240 mg/m2/day, 5 of 10 children experienced durable suppression of plasma p24 antigen to <50% of baseline values through 8 weeks of nevirapine monotherapy. Viruses resistant to nevirapine were isolated from all children during therapy, but their isolation did not always predict loss of antiviral activity. The evaluation of nevirapine in combination therapy trials is underway in children.

Original languageEnglish (US)
Pages (from-to)713-721
Number of pages9
JournalJournal of Infectious Diseases
Issue number4
StatePublished - 1996

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children'. Together they form a unique fingerprint.

Cite this